New Age Alpha Advisors LLC Boosts Stock Holdings in United Therapeutics Corporation (NASDAQ:UTHR)

New Age Alpha Advisors LLC lifted its position in shares of United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 97.6% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 9,162 shares of the biotechnology company's stock after buying an additional 4,525 shares during the quarter. New Age Alpha Advisors LLC's holdings in United Therapeutics were worth $2,824,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of UTHR. Ruffer LLP boosted its stake in United Therapeutics by 25.5% during the first quarter. Ruffer LLP now owns 14,374 shares of the biotechnology company's stock worth $4,431,000 after acquiring an additional 2,925 shares in the last quarter. Cumberland Partners Ltd boosted its stake in United Therapeutics by 84.2% during the first quarter. Cumberland Partners Ltd now owns 3,500 shares of the biotechnology company's stock worth $1,079,000 after acquiring an additional 1,600 shares in the last quarter. PNC Financial Services Group Inc. boosted its stake in United Therapeutics by 27.5% during the first quarter. PNC Financial Services Group Inc. now owns 4,059 shares of the biotechnology company's stock worth $1,251,000 after acquiring an additional 875 shares in the last quarter. Jupiter Asset Management Ltd. bought a new position in United Therapeutics during the first quarter worth $15,607,000. Finally, Blueshift Asset Management LLC bought a new position in United Therapeutics during the first quarter worth $523,000. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

UTHR has been the topic of several research analyst reports. Morgan Stanley cut their target price on shares of United Therapeutics from $348.00 to $328.00 and set an "equal weight" rating on the stock in a research note on Thursday, July 10th. UBS Group cut their target price on shares of United Therapeutics from $410.00 to $385.00 and set a "buy" rating on the stock in a research note on Monday, June 30th. Wall Street Zen lowered shares of United Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Friday, May 2nd. JPMorgan Chase & Co. dropped their price objective on shares of United Therapeutics from $350.00 to $330.00 and set an "overweight" rating on the stock in a research note on Tuesday, July 8th. Finally, Wells Fargo & Company dropped their price objective on shares of United Therapeutics from $314.00 to $295.00 and set an "equal weight" rating on the stock in a research note on Thursday, July 31st. Four investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $379.69.

United Therapeutics Price Performance

Shares of UTHR stock traded up $2.08 on Friday, hitting $301.50. The stock had a trading volume of 519,284 shares, compared to its average volume of 605,134. The business has a 50 day moving average of $296.64 and a 200 day moving average of $311.43. The stock has a market cap of $13.60 billion, a price-to-earnings ratio of 11.77, a price-to-earnings-growth ratio of 4.54 and a beta of 0.57. United Therapeutics Corporation has a 12-month low of $266.98 and a 12-month high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 EPS for the quarter, missing the consensus estimate of $6.80 by ($0.39). The firm had revenue of $798.60 million during the quarter, compared to analysts' expectations of $802.13 million. United Therapeutics had a net margin of 40.36% and a return on equity of 18.73%. The business's revenue for the quarter was up 11.7% on a year-over-year basis. During the same quarter in the prior year, the company earned $5.85 EPS. As a group, research analysts expect that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

Insider Activity at United Therapeutics

In related news, Director Nilda Mesa sold 645 shares of the firm's stock in a transaction dated Tuesday, June 24th. The shares were sold at an average price of $289.99, for a total transaction of $187,043.55. Following the completion of the sale, the director owned 4,883 shares in the company, valued at approximately $1,416,021.17. This trade represents a 11.67% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Paul A. Mahon sold 11,000 shares of the firm's stock in a transaction dated Thursday, August 7th. The stock was sold at an average price of $300.00, for a total transaction of $3,300,000.00. Following the sale, the executive vice president owned 36,781 shares of the company's stock, valued at $11,034,300. This trade represents a 23.02% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 81,681 shares of company stock worth $24,618,359. 10.30% of the stock is currently owned by corporate insiders.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.